Accord enters Europe as Coherus stays quiet
Accord Healthcare has capitalised on its market-leading European Commission approval for Pelgraz (pegfilgrastim) by making “meaningful sales” of the biosimilar neutropenia treatment in Germany within two days of launching. A trade introduction of Pelgraz in the UK is also underway, a company spokesperson told Generics bulletin.
You may also be interested in...
Firms that achieved recognition at last year’s Global Generics & Biosimilars Awards have continued to build on that success in the months since.
Juta Pharma has received a positive opinion from the European Medicines Agency’s CHMP recommending granting a pan-European marketing authorization for its biosimilar pegfilgrastim, Grasustek.
Following launches of Mundipharma’s Pelmeg biosimilar pegfilgrastim in Germany, Ireland and the Netherlands, Napp is now rolling the product out in the UK.